Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02982902 · ClinicalTrials.gov registry record · Early Phase 1
T Cell Therapy of Opportunistic Cytomegalovirus Infection
A Early Phase 1 study of Cytomegalovirus Infections and Hematopoietic Stem Cell Transplant, sponsored by Mari Dallas.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02982902 is a Early Phase 1 study of Cytomegalovirus Infections and Hematopoietic Stem Cell Transplant that is actively recruiting participants, run by Mari Dallas. The registered enrollment target is 20 participants, below the 202-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02982902, a Early Phase 1 study of Cytomegalovirus Infections and Hematopoietic Stem Cell Transplant, is actively recruiting participants, sponsored by Mari Dallas.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if a specific type of cell-based immunotherapy, using T-cells from a donor that are specific against cytomegalovirus (CMV) is feasible to treat infections by CMV. Adoptive T-cell therapy is an investigational (experimental) therapy that works by using the blood of a donor and selecting the T-cells that can respond against a specific infectious entity. These selected T-cells are then infused to the patient, to try to give the immune system the ability to fight the infection. Adoptive T-cell therapy is experimental because it is not approved by the Food and Drug Administration (FDA).
Conditions Studied
Interventions
- BIOLOGICAL CMV specific adoptive t-cells
Study Locations (1)
Ohio
- University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-05-27 |
| Est. Completion | 2028-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02982902
The ClinicalTrials.gov registry entry for NCT02982902 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 202-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (90% lower). The listed sponsor is Mari Dallas, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cytomegalovirus Infections appearing as the primary indexed condition, and to 1 intervention - of which CMV specific adoptive t-cells is the first listed.
NCT02982902 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT02982902 about?
NCT02982902 is a clinical study titled "T Cell Therapy of Opportunistic Cytomegalovirus Infection". The purpose of this study is to determine if a specific type of cell-based immunotherapy, using T-cells from a donor that are specific against cytomegalovirus (CMV) is feasible to treat infections by CMV. Adoptive T-cell therapy is an investigational (experimental) therapy that works by using the b...
What is the current status of trial NCT02982902?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2020-05-27. Estimated completion is 2028-08.
What conditions does trial NCT02982902 study?
This clinical trial studies the following conditions: Cytomegalovirus Infections, Hematopoietic Stem Cell Transplant, Opportunistic Infections.
What interventions are being tested in trial NCT02982902?
The interventions under investigation include: CMV specific adoptive t-cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT02982902?
This trial is sponsored by Mari Dallas, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02982902 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytomegalovirus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
RECRUITING · Phase 4
-
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
RECRUITING · Phase 2
-
Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study
RECRUITING
-
R-MVST Cells for Treatment of Viral Infections
RECRUITING · Phase 1
-
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
RECRUITING · Phase 1
-
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.